MX2019013815A - Inhibidor de antigenos de superficie del virus de la hepatitis b. - Google Patents

Inhibidor de antigenos de superficie del virus de la hepatitis b.

Info

Publication number
MX2019013815A
MX2019013815A MX2019013815A MX2019013815A MX2019013815A MX 2019013815 A MX2019013815 A MX 2019013815A MX 2019013815 A MX2019013815 A MX 2019013815A MX 2019013815 A MX2019013815 A MX 2019013815A MX 2019013815 A MX2019013815 A MX 2019013815A
Authority
MX
Mexico
Prior art keywords
hepatitis
surface antigen
virus surface
antigen inhibitor
formula
Prior art date
Application number
MX2019013815A
Other languages
English (en)
Inventor
Charles Z Ding
Shuhui Chen
Fei Sun
Yanbin Hu
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of MX2019013815A publication Critical patent/MX2019013815A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente invención se describe un nuevo derivado del ácido 11-oxo-7,11-dihidro-6h-benzo-[f]pirido[1,2-d][1,4]azepin oxepin-10-carboxílico que sirve como inhibidor del antígeno de superficie del virus de la hepatitis B. Se describen específicamente un compuesto representado por la fórmula (V) o una sal farmacéuticamente aceptable del mismo, y las aplicaciones del compuesto representado por la fórmula (V) o la sal farmacéuticamente aceptable del mismo y una composición farmacéutica del mismo en el tratamiento de la hepatitis B viral. (ver formula).
MX2019013815A 2017-05-22 2018-05-22 Inhibidor de antigenos de superficie del virus de la hepatitis b. MX2019013815A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710365328 2017-05-22
PCT/CN2018/087852 WO2018214875A1 (zh) 2017-05-22 2018-05-22 乙型肝炎病毒表面抗原抑制剂

Publications (1)

Publication Number Publication Date
MX2019013815A true MX2019013815A (es) 2020-07-28

Family

ID=64396235

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013815A MX2019013815A (es) 2017-05-22 2018-05-22 Inhibidor de antigenos de superficie del virus de la hepatitis b.

Country Status (11)

Country Link
US (1) US20200197409A1 (es)
EP (1) EP3632914B1 (es)
JP (1) JP7072003B2 (es)
KR (1) KR102546873B1 (es)
CN (1) CN110372723B (es)
AU (1) AU2018271643B2 (es)
BR (1) BR112019024393A2 (es)
CA (1) CA3062499A1 (es)
EA (1) EA039824B1 (es)
MX (1) MX2019013815A (es)
WO (1) WO2018214875A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110066278B (zh) 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
CA3111792A1 (en) 2018-09-05 2020-03-12 Children's Medical Center Corporation Papd5 inhibitors and methods of use thereof
EP3856740A4 (en) 2018-09-30 2021-12-15 Sunshine Lake Pharma Co., Ltd. CONDENSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
BR112021009770A2 (pt) * 2018-11-22 2021-08-17 Fujian Cosunter Pharmaceutical Co., Ltd. forma cristalina de inibidor de antígeno de superfície de hepatite b
US20220306648A1 (en) 2019-08-15 2022-09-29 Fujian Akeylink Biotechnology Co., Ltd. Preparation Method for Oxazepine Compound
WO2021228213A1 (zh) 2020-05-15 2021-11-18 福建广生堂药业股份有限公司 包含三并环类化合物的组合及其在制备治疗hbv药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131134A1 (en) 2007-04-17 2008-10-30 Cylene Pharmaceuticals, Inc. Hydrazide compounds and uses thereof
CN105899508B (zh) * 2014-01-30 2017-07-04 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新型二氢喹嗪酮类化合物
WO2017013046A1 (en) * 2015-07-21 2017-01-26 F. Hoffmann-La Roche Ag Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
CA3031063A1 (en) * 2016-07-29 2018-02-01 Newave Pharmaceutical Inc. Benzo-quinolizin-2oxo carboxylic acid derivatives for the treatment of hbv infection
KR102522060B1 (ko) * 2016-11-07 2023-04-14 아뷰터스 바이오파마 코포레이션 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법

Also Published As

Publication number Publication date
KR102546873B1 (ko) 2023-06-26
JP7072003B2 (ja) 2022-05-19
EA201992771A1 (ru) 2020-03-23
AU2018271643B2 (en) 2022-06-02
CA3062499A1 (en) 2018-11-29
AU2018271643A1 (en) 2020-01-02
EP3632914A1 (en) 2020-04-08
JP2020520958A (ja) 2020-07-16
KR20200027925A (ko) 2020-03-13
CN110372723A (zh) 2019-10-25
CN110372723B (zh) 2022-05-31
BR112019024393A2 (pt) 2020-06-09
EA039824B1 (ru) 2022-03-17
EP3632914A4 (en) 2020-04-22
WO2018214875A1 (zh) 2018-11-29
EP3632914B1 (en) 2022-08-31
US20200197409A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
EA038122B9 (ru) Ингибитор поверхностного антигена вируса гепатита b
MX2019013815A (es) Inhibidor de antigenos de superficie del virus de la hepatitis b.
PH12018550201A1 (en) Hepatitis b antiviral agents
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018550148A1 (en) Hepatitis b antiviral agents
PH12018501736A1 (en) Tetracyclic pyridone compounds as antivirals
MX2020010737A (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
WO2019143902A3 (en) Substituted heterocycles as antiviral agents
SG11201901894TA (en) Anti-influenza virus pyrimidine derivatives
PH12020550065A1 (en) Hepatitis b antiviral agents
PH12020550256A1 (en) 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors
MD4754C1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
NZ703064A (en) Inhibitors of hepatitis c virus
MX2017010506A (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
AU2018253590A1 (en) Imidazopyridazine compounds
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
GEP20227373B (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
EA202192512A1 (ru) Пиримидоновые производные с конденсированными кольцами для применения в лечении инфекции, вызванной hbv, или заболеваний, вызванных hbv
SA112330457B1 (ar) مشتقات فينيل- ايزواوكسازول وعملية تحضيرها
WO2017034242A3 (ko) 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물
WO2015191526A3 (en) Antiviral compounds
IN2011CH03893A (es)
MX2019011173A (es) Compuesto que contiene silicio para la resistencia a la infeccion por el virus de la hepatitis c.